サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1402197

抗体治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023年～2030年、予測

Global Antibody Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 221 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
抗体治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023年～2030年、予測
出版日: 2023年12月01日
発行: Value Market Research
ページ情報: 英文 221 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体治療薬市場の世界需要は、調査期間2023年～2030年のCAGR15.21%で、2022年の2,591億4,000万米ドルから2030年には8,043億8,000万米ドル近くの市場規模に達すると推定されます。

抗体治療薬は、治療用抗体または生物学的薬剤としても知られ、免疫系によって産生される抗体から開発される医薬品の一種です。これらの抗体は、主にマウスやウサギなどの動物から工学的に作製されるか、またはそれに由来するもので、様々な疾患の治療薬として使用されるように改良されます。

市場力学

抗体治療薬市場は、その大幅な成長に寄与する様々な要因によって牽引されています。がん、自己免疫疾患、感染症などの慢性疾患の増加により、抗体療法が提供する正確で標的を絞った治療に対する需要が高まっています。バイオテクノロジー、特に抗体工学と抗体製造の進歩は、より効果的で安全な治療法につながり、多様な医療分野への応用を拡大しています。研究開発、特に新たな標的や革新的な抗体フォーマットの探求への投資は、市場の拡大をさらに後押ししています。個別化医療へのシフトは抗体治療薬に有利であり、個々の患者に合わせた治療を可能にします。臨床試験の成功や規制当局の承認は、医療従事者や患者の間でこうした治療法に対する信頼を高め、採用率を押し上げています。ヘルスケア支出の増加、業界プレイヤー間の協力、さまざまな医療領域における抗体ベースの治療法の適用範囲の拡大は、抗体治療薬市場の堅調な成長に総体的に寄与しており、これらの治療法は現代医療の最前線に位置付けられています。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、抗体治療薬の世界市場における各セグメントを包括的に評価することもできます。抗体治療薬産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける抗体治療薬市場の現在および将来の需要を強調する地域展望を取り上げます。さらに、著名な全地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 抗体治療薬 - 業界分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 抗体治療薬の世界市場分析：フォーマット別

  • フォーマット別概要
  • 実績データと予測データ
  • フォーマット別分析
  • モノクローナル抗体
  • ポリクローナル抗体療法
  • 二特異性抗体
  • 抗体フラグメント
  • その他

第6章 抗体治療薬の世界市場分析：疾患領域別

  • 疾患領域別概要
  • 実績データと予測データ
  • 疾患領域別分析
  • 自己免疫疾患・炎症性疾患
  • 腫瘍学
  • 血液疾患
  • 感染症
  • 骨学
  • 免疫学
  • 神経学
  • その他

第7章 抗体医薬の世界市場分析：投与経路別

  • 投与経路別概要
  • 実績データと予測データ
  • 投与経路別分析
  • 静脈内投与
  • 皮下投与
  • その他

第8章 世界の抗体治療薬市場分析：供給源別

  • 供給源別概要
  • 実績データと予測データ
  • 供給源別分析
  • ヒト
  • ヒト化抗体
  • キメラ
  • その他

第9章 抗体治療薬の世界市場分析：エンドユーザー別

  • エンドユーザー別概要
  • 実績データと予測データ
  • エンドユーザー別分析
  • 病院
  • 長期療養施設
  • その他

第10章 世界の抗体治療薬市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別売上分析
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第11章 抗体治療薬企業の競合情勢

  • 抗体治療薬市場の競合
  • 提携・共同研究・契約
  • 合併・買収
  • 新製品上市
  • その他の開発

第12章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • F. Hoffmann-La Roche Ltd.（Switzerland）
  • AbbVie Inc.（US）
  • Johnson & Johnson（US）
  • Merck KGaA（Germany）
  • Bristol-Myers Squibb（US）
  • AstraZeneca（UK）
  • Sanofi（France）
  • Regeneron Pharmaceuticals Inc.（US）
  • Novartis AG（Switzerland）
  • Amgen Inc.（US）
  • Biogen Inc.（US）
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis by Format (USD MN)
  • Monoclonal Antibody Market Sales by Geography (USD MN)
  • Polyclonal Antibody Therapy Market Sales by Geography (USD MN)
  • Bispecific Antibody Market Sales by Geography (USD MN)
  • Antibody Fragment Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis Market by Disease Areas (USD MN)
  • Autoimmune & Inflammatory Diseases Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Hematology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Osteology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis by Route Of Administration (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Subcutaneous Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis by Source (USD MN)
  • Human Market Sales by Geography (USD MN)
  • Humanized Market Sales by Geography (USD MN)
  • Chimeric Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis by End User (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Long-term Care Facilities Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Antibody Therapeutics Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Antibody Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Antibody Therapeutics Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Format
  • Market Attractiveness Analysis by Disease Areas
  • Market Attractiveness Analysis by Route Of Administration
  • Market Attractiveness Analysis by Source
  • Market Attractiveness Analysis by End User
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Format (USD MN)
  • Monoclonal Antibody Market Sales by Geography (USD MN)
  • Polyclonal Antibody Therapy Market Sales by Geography (USD MN)
  • Bispecific Antibody Market Sales by Geography (USD MN)
  • Antibody Fragment Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by Disease Areas (USD MN)
  • Autoimmune & Inflammatory Diseases Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Hematology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Osteology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by Route Of Administration (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Subcutaneous Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by Source (USD MN)
  • Human Market Sales by Geography (USD MN)
  • Humanized Market Sales by Geography (USD MN)
  • Chimeric Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by End User (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Long-term Care Facilities Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112113173

The global demand for Antibody Therapeutics Market is presumed to reach the market size of nearly USD 804.38 BN by 2030 from USD 259.14 BN in 2022 with a CAGR of 15.21% under the study period 2023 - 2030.

Antibody therapeutics, also known as therapeutic antibodies or biological drugs, are a class of medications developed from antibodies produced by the immune system. These antibodies can be engineered or derived from animals, primarily mice or rabbits, and then modified to be used as treatments for various diseases.

MARKET DYNAMICS

The Antibody therapeutics market is driven by various factors contributing to its substantial growth. Increasing incidences of chronic diseases like cancer, autoimmune disorders, and infectious ailments fuel the demand for precise, targeted treatments that antibody therapies offer. Advancements in biotechnology, particularly in antibody engineering and manufacturing, lead to more effective and safer therapies, expanding their applications across diverse medical fields. Investments in research and development, especially in exploring new targets and innovative antibody formats, further propel market expansion. The shift toward personalized medicine favors antibody therapeutics, allowing tailored treatments for individual patients. Successful clinical trials and regulatory approvals bolster confidence in these therapies among healthcare professionals and patients, driving adoption rates. Rising healthcare expenditure, collaborations among industry players, and the broadening scope of antibody-based treatments in various medical domains collectively contribute to the robust growth of the Antibody therapeutics market, positioning these therapies at the forefront of modern medicine.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of antibody therapeutics. The growth and trends of antibody therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the antibody therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Format

  • Monoclonal Antibody
  • Polyclonal Antibody Therapy
  • Bispecific Antibody
  • Antibody Fragment
  • Other

By Disease Areas

  • Autoimmune & Inflammatory Diseases
  • Oncology
  • Hematology
  • Infectious Diseases
  • Osteology
  • Immunology
  • Neurology
  • Other

By Route Of Administration

  • Intravenous
  • Subcutaneous
  • Other

By Source

  • Human
  • Humanized
  • Chimeric
  • Other

By End User

  • Hospitals
  • Long-Term Care Facilities
  • Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antibody Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antibody Therapeutics market include F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ANTIBODY THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Format
    • 3.7.2 Market Attractiveness Analysis By Disease Areas
    • 3.7.3 Market Attractiveness Analysis By Route Of Administration
    • 3.7.4 Market Attractiveness Analysis By Source
    • 3.7.5 Market Attractiveness Analysis By End User
    • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY FORMAT

  • 5.1 Overview by Format
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Format
  • 5.4 Monoclonal Antibody Historic and Forecast Sales by Regions
  • 5.5 Polyclonal Antibody Therapy Historic and Forecast Sales by Regions
  • 5.6 Bispecific Antibody Historic and Forecast Sales by Regions
  • 5.7 Antibody Fragment Historic and Forecast Sales by Regions
  • 5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY DISEASE AREAS

  • 6.1 Overview by Disease Areas
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Disease Areas
  • 6.4 Autoimmune & Inflammatory Diseases Historic and Forecast Sales by Regions
  • 6.5 Oncology Historic and Forecast Sales by Regions
  • 6.6 Hematology Historic and Forecast Sales by Regions
  • 6.7 Infectious Diseases Historic and Forecast Sales by Regions
  • 6.8 Osteology Historic and Forecast Sales by Regions
  • 6.9 Immunology Historic and Forecast Sales by Regions
  • 6.10. Neurology Historic and Forecast Sales by Regions
  • 6.11 Other Historic and Forecast Sales by Regions

7 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1 Overview by Route Of Administration
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Route Of Administration
  • 7.4 Intravenous Historic and Forecast Sales by Regions
  • 7.5 Subcutaneous Historic and Forecast Sales by Regions
  • 7.6 Other Historic and Forecast Sales by Regions

8 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY SOURCE

  • 8.1 Overview by Source
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Source
  • 8.4 Human Historic and Forecast Sales by Regions
  • 8.5 Humanized Historic and Forecast Sales by Regions
  • 8.6 Chimeric Historic and Forecast Sales by Regions
  • 8.7 Other Historic and Forecast Sales by Regions

9 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY END USER

  • 9.1 Overview by End User
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by End User
  • 9.4 Hospitals Historic and Forecast Sales by Regions
  • 9.5 Long-term Care Facilities Historic and Forecast Sales by Regions
  • 9.6 Other Historic and Forecast Sales by Regions

10 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. South East Asia Sales Analysis
    • 10.5.10. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ANTIBODY THERAPEUTICS COMPANIES

  • 11.1. Antibody Therapeutics Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF ANTIBODY THERAPEUTICS INDUSTRY

  • 12.1. Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. AbbVie Inc. (US)
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Johnson & Johnson (US)
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. Merck KGaA (Germany)
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. Bristol-Myers Squibb (US)
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. AstraZeneca (UK)
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. Sanofi (France)
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Regeneron Pharmaceuticals Inc. (US)
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments
  • 12.11. Novartis AG (Switzerland)
    • 12.11.1. Company Overview
    • 12.11.2. Company Revenue
    • 12.11.3. Products
    • 12.11.4. Recent Developments
  • 12.12. Amgen Inc. (US)
    • 12.12.1. Company Overview
    • 12.12.2. Company Revenue
    • 12.12.3. Products
    • 12.12.4. Recent Developments
  • 12.13. Biogen Inc. (US)
    • 12.13.1. Company Overview
    • 12.13.2. Company Revenue
    • 12.13.3. Products
    • 12.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies